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Abstract
Background: Salivary Glands Malignant Neoplasms (SGMNs) account for 3-6% of head and neck cancers and 0.3%
of all cancers. Tumor cells that express CD44 and CD24 exhibit a stem-cell-like behavior. CD44 is the binding site for
hyaluronic acid, and CD24 is a receptor that interacts with P-selectin to induce metastasis and tumor progression.
The present study aims to evaluate the expression of CD44 and CD24 on SGMNs and correlated these data with
several clinicopathologic features.
Methods: Immunohistochemical stains for CD44 and CD24 were performed on tissue microarrays containing SGMN
samples from 69 patients. The CD44, CD24 and CD44/CD24 expression phenotypes were correlated to patient
clinicopathologic features and outcome.
Results: CD44 expression was associated with the primary site of neoplasm (p = 0.046). CD24 was associated
with clinical stage III/IV (p = 0.008), T stage (p = 0,27) and lymph node (p = 0,001). The CD44/CD24 profiles were
associated with the primary site of injury (p = 0.005), lymph node (p = 0.011) and T stage (p = 0.023). Univariate
analysis showed a significant relationship between clinical staging and disease- free survival (p = 0.009), and the
overall survival presents relation with male gender (p = 0.011) and metastasis (p = 0.027).
Conclusion: In summary, our investigation confirms that the clinical stage, in accordance with the literature, is the
main prognostic factor for SGMN. Additionally, we have presented some evidence that the analysis of isolated
CD44 and CD24 immunoexpression or the two combined markers could give prognostic information associated to
clinicopathologic features in SGMN.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1284611098470676.
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Background
Salivary Glands Malignant Neoplasms (SGMNs) are re-
latively rare malignant solid tumors. They represent a
group of tumors that present favorable features concer-
ning to loco-regional invasion and metastasis [1]. The
estimated global incidence rate of SGMN varies from 0.4
to 2.6 cases per 100,000 people [2]. Because SGMNs
account for 3% to 6% of all head and neck cancers, it
represents only 0.3% of all human malignancies [3].
Following the discovery of hematopoietic stem cells,
the “cancer stem cell” theory was proposed [4-7]. Cur-
rently, the most accepted theory for the etiopathogenesis
of cancer is that the tumor starts as a single cell that
shares some features with normal stem cells (SC) [4-6].
This cancer stem cell (CSC) may be involved in can-
cer initiation, maintenance of tumor growth, progres-
sion, tumor recurrence [6] and may also predict tumor
treatment outcome [4]. SC and CSC have been identified
in most tissues and solid tumors including in the brain
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[8], colon [9], breast [10] melanocytic cells [11], pancreas
[12] and prostate [13].
There is evidence that tumor cells which express
CD44 and CD24, exhibit a stem-cell-like behavior. CD44
is an important receptor for hyaluronate (HA) [14]. The
functions of this transmembrane receptor include coor-
dination of cell motility, cell-cell adhesion, lymphocyte
activation [15], cell migration and cellular-extracellular
matrix interaction [14]. Besides the interaction with
HA, the CD44 protein has also been shown to interact
with other proteins in the extracellular matrix including
fibronectin, collagen types I and IV, serglycin and os-
teopontin [16]. The CD44 receptor is one of the most
frequently studied SC markers [17], and CD44 expres-
sion is associated with epithelial tumors, although the
results show different correlations in each tissue ana-
lyzed. Increased CD44 expression has been observed in
aggressive gastric cancer [18]. Wielenga et al. [19] de-
monstrated that CD44 variant, v6, is strongly related to
tumor progression, supporting the concept that CD44
plays an important role in human colorectal tumor me-
tastasis. However, irregular or low expression of CD44
was related to poor prognoses in oral squamous cells
carcinoma [16,20-22].
CD24 is a glycosylphosphatidylinositol-linked cell sur-
face glycoprotein [23]. It has been identified as a P-
selectin ligand and adhesion receptor for platelets and
activated endothelial cells [24]. The CD24 protein is
expressed in keratinocytes, renal tubules, regenerating
muscles and the developing brain and pancreas [23]. It
may be involve as a regulator factor for the control of
cell proliferation, cell adhesion and apoptosis. However,
the expression and physiological function of CD24 in
human malignancies has not yet been completely eluci-
dated [23]. In human carcinomas, there is evidence that
CD24 expression is related to prognosis [25] and may
contribute to metastasizing tumor cells [24], but the re-
lationship between CD24 and prognosis is not com-
pletely understood.
Some studies have reported the correlation between
CSC and unregulated expression of CD44 and CD24
[10,12]. However, the existence of CSCs in SGMN and
their (CSCs) putative influence on the behavior of SGMN
merit further investigation. Thus, the present study aim to
investigates the expression of CD44 and CD24 in SGMNs
and the association of CD44/CD24 immunophenotypes to
the clinicopathologic features of SGMNs.
Methods
Subjects
Sixty-nine cases of SGMN, diagnosed between 1990 and
2009, were retrieved from the medical files of the De-
partment of Pathology, Ribeirão Preto Medical School,
University of São Paulo, Brazil. The medical files were
analyzed to collect information on age, gender, primary
anatomic localization, tumor evolution, history of smok-
ing and alcohol intake, histological classification, nodal
status, treatment, tumor recurrences, disease-free sur-
vival (DFS) and overall survival (OS). The study protocol
conformed to the ethical guidelines of the 1975 Decla-
ration of Helsinki and was carried out with the approval
of the Ribeirão Preto Medical School Human Research
Ethics Committee.
The following inclusion criteria were applied: 1) suf-
ficient of clinicopathologic data; 2) histological diagnosis
of mucoepidermoid carcinoma (MC), adenoid cystic car-
cinoma (ACC), acinic cell adenocarcinoma (ACA), ade-
nocarcinoma (nos) (A (nos)), carcinoma ex-pleomorphic
adenoma (Cex-PA), salivary duct carcinoma (SDC), poly-
morphous low-grade adenocarcinoma (PLGA), basal cell
adenocarcinoma (BCA) or malignant myoepithelial neo-
plasm (MMN) (diagnoses as defined by the World Health
Organization)) [26]; 3) no previous head and neck can-
cer; 4) no prior oncologic therapy. In accordance with
Wittekind et al. [27] all cases were staged according to
TMN classification.
For statistical analysis, the smoking and alcohol intake
history was dichotomized: the patients were classified as
“current consumers” or “never consumers”. Current con-
sumers of tobacco were those individuals who used a
cigarette, pipe, and/or cigar daily, and current alcohol
consumption was defined as daily use of wine, beer, and/
or other distilled drinks. “Never consumers” were those
who had quit alcohol and/or tobacco consumption more
than 12 months prior to diagnosis.
Tissue Micro-Array (TMA)
Hematoxylin and eosin (H&E) stained slides from 69
cases of SGMNs were reviewed by an experienced path-
ologist (ARS) to detect the most significant tumor areas.
These areas were then selected for assembly into the
TMA paraffin block. Representative 2-mm cores from se-
lected areas from each tumor were detached and allocated
to a recipient paraffin block using a manual tissue-ar-
raying instrument (“Tissue Micro-Array Builder,” Histo-
pathology, Ltd., Akác u. 8, 7632 Pécs, Hungary, Baranya).
Three-micrometer-thick sections were cut from the TMA
paraffin blocks using a paraffin tape-transfer system
(Instrumedics, Saint Louis, MO, USA). The first and
final sections were stained with H&E to confirm the
presence of SGMN by light microscopy.
Immunohistochemistry (IHC)
All 69 samples were fixed in 4% neutral formalin and
embedded in paraffin. Three-micrometer-thick sections
were cut from the TMA paraffin blocks. The sections
were dewaxed in xylene and rehydrated by immersing
in a series of graded alcohols. Endogenous peroxidases
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were blocked using a solution containing 0.3% hydrogen
peroxide for 30 min. The paraffin sections were then
placed in 10 mM citrate buffer and submitted to heat re-
trieval, using a vapor lock, for 40 min. Following antigen
retrieval, the slides were allowed to cool at room tem-
perature for 30 min, and the sections were then in-
cubated with the primary antibody at 4°C overnight.
The dilution, clone and source of the antibodies used
in this study were CD44 (mouse monoclonal antibody
1:100, clone DF1485, Novocastra, Newcastle upon Tyne,
United Kingdom) and CD24 (mouse monoclonal anti-
body 1:50, clone SN3b, Thermo Scientific, Fremont, CA,
USA). Following overnight incubation with the approp-
riate primary antibody, all sections were incubated with
post-primary solution, for 30 minutes, and then incuba-
ted with the polymer (both provided by Biocare Medical
Mach 4 Universal Polymer Detection System, Concord,
California, USA) for 30 minutes. The reaction was deve-
loped by adding diaminobenzidine (DAB), and the sec-
tions were counterstained with hematoxylin. Finally, the
slides were dehydrated in a graded series of alcohols and
mounted with permount. The percentages of CD44 and
CD24 positive cancer cells were determined by two ob-
servers (ARS and LRO) with a blind fashion. Discrepan-
cies between the observers were resolved by conference,
achieving consensus for each case.
The IHC reaction was carried out on two slides at dif-
ferent depth levels through the tumor to increase the ac-
curacy and the robustness of the array-based data.
Negative controls were prepared by omitting the primary
antibody, for the both antibodies were used human ton-
sil tissue as positive controls. In accordance with pro-
tocols devised by Honeth and colleagues [28] CD44
staining was detect in the membrane and scoring was as
follows: 0, 0% positive tumor cells; 1, 1% to 10% positive
cells; 2, 11% to 50% positive cells; 3, 51% to 75% positive
cells; and 4, 76% to 100% positive cells. The cases classi-
fied as 1 or superior were considered positive to quantita-
tive analysis. The quantification of CD24 was evaluated in
accordance with protocols devised by Kristiansen and
colleagues [29]. CD24 staining was detected in the mem-
brane and cytoplasm. Negative controls showed no signs
of staining, as positive controls were used human tonsil
tissue. Cases presenting unequivocal staining [29] were
classified as positive.
For prognostic investigation and survival analysis, the
immunophenotypes patterns were grouped: CD44 + /
CD24+ (CD44 positive case/CD24 positive CD44 + /
CD24- (CD44 positive case/CD24 negative case), CD44-/
CD24+ (CD44 negative case/CD24 positive case), CD44-
/CD24- (CD44 negative case/CD24 negative case). The
double-immunolabeling study was performed according
to the manufacturer’s protocol (EnVision Doublestain
System; Dako, Carpinteria, CA, USA). The CD44 was
developed with DAB (brown), and the CD24 was
developed with fast red (red) (Figure 1D).
Statistical analysis
Statistical analyses were performed using the commer-
cially available PASW Statistics 18.0 software (Chicago,
IL, USA). The correlations of CD44, CD24 expression
and clinicopathologic features were tested with contin-
gency tables using Fisher’s exact test (two variables) or
χ2 (three or more variables) tests. The OS rate was de-
fined as the interval between the diagnosis and the date
of death (uncensored data) or the date of the last avail-
able clinical information (censored data). The DFS was
defined as the time from diagnosis until the occurrence
of local recurrence or metastasis. Univariate analyses
were performed using Kaplan-Meier curves and the log-
rank test to compare and estimate cumulative survival
rates. Multivariate Cox proportional hazard regression
was used to correlate the risk factors with independent
prognostic properties. Due to their limited number, the
CD44-/CD24+ cases were removed from analyses. All
tests were two- tailed and P-values < 0.05 were consi-
dered statistical significance.
Results
Patient demographics and clinical data
A total of 69 patients with SGMN (28 men (40.5%) and
41 women (59.5%) were used for the immunohistoche-
mical study. Age ranged from 13 to 85 years with a
mean age of 54,8 years. The age of male range from 23
and 85 years, with a mean age of 58 years. The ages of
female were range from 13 and 85 years (average 51.5 -
years). Information on history of smoking and alcohol
intake showed a total of 23 (33.3%) tobacco users and 14
(20.3%) alcohol users.
In the present study, 27 (39.1%) tumors were found in
the parotid gland, 13 (18.8%) tumors in the submandibu-
lar gland, 27 (39.1%) tumors in the minor salivary glands
and 2 tumors (2.9%) in the sublingual gland.
The neoplasms were classified as mucoepidermoid
carcinoma (11 cases (15.9%)), adenoid cystic carcinoma
(34 cases (49.3%)), acinic cell adenocarcinoma (4 cases
(5.8%)), adenocarcinoma ,NOS (5 cases (7.2%)), poly-
morphous low-grade adenocarcinoma (3 cases (4.3%)),
basal cell adenocarcinoma (5 cases (7.2%)), carcinoma
ex- pleomorphic adenoma (4 cases (5.8%)), and salivary
duct carcinoma (3 cases (4.3%)).
The diameter of the tumors ranged from 0.3 cm to
8.0 cm. Twenty-five cases (36.2%) were classified as T1
tumors and 17 cases (24.6%) were T2 tumors, 16 cases
(23.2%) were T3 tumors, 11 cases (15.9%) were T4 tu-
mors. In these samples, 16 cases (23.2%) were classified
as being in stage I, 8 cases (11.6%) were in stage II, 11
(15.9%) cases were in stage III and 34 cases (49.3%) were
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classified as being in stage IV. All 69 patients underwent
surgical treatment. Following the surgical treatment,
50 patients received adjuvant therapy, 30 patients re-
ceived only radiotherapy, 4 received only chemother-
apy and 16 patients were received both chemotherapy
and radiotherapy.
Metastases developed in 26 patients, 24 patients deve-
loped loco-regional recurrence, 11 patients developed
lymph node metastasis and 21 patients died during the
course of the study. The disease-free survival and the
overall survival ranged from 1 month to 248 months
(the DFS mean was 52 months and OS mean was 62 -
months). The clinical features are summarized in Table 1.
Statistical analysis of SGMN clinicopathologic features
Clinicopathologic features (gender, age, smoking and al-
cohol intake history, lymph node metastases, clinical and
T stage, loco-regional recurrence, metastasis and death)
were tested with contingency tables using Fisher’s exact
test (two variables) or χ2 (three or more variables) tests
and P-values < 0.05 were considered statistical signifi-
cance. The present data shown association between gen-
der and death, were observed that male patients had a
high number of death events during the course of the
study (p = 0.017), The metastasis process has also pre-
sents a relation with death (p = 0,007), positive metasta-
sis patients presents increased death proportion. Our
research has also found association between local-re-
currence, clinical stage and metastases. The analysis
demonstrates a higher proportion of patients positives to
local-recurrence associated to advanced clinical stage
(III and IV) (p = 0.044) and were observed, during the
course of the study, patients presenting local-recurrence
had a high propensity to distant metastasis (p = 0.010).
All the remaining statistical comparison of clinicopatho-
logic features were considered no statistical significant.
Immunohistochemical findings and their relationship to
clinicopathologic features
The positive controls to CD44 and CD24 were used hu-
man tonsil tissue. We observed in normal salivary glands
CD44 widely expressed by acinar cells (membranous
stain), however CD24 do not present staining (membra-
nous and citoplasmatic stain), in normal gland. CD44
membrane expression (Figure 1A) was verified in 50 of
69 cases (72.4%). Eighteen cases were positive for CD24
(Figure 1B).
The CD44 expression on Adenoid cystic (26 cases)
was moderate to strong staining, cytoplasmic and mem-
branous was observed on myoepithelial component. Mu-
coepidermoid carcinoma positive cases (7 cases) showed
weak to strong patchy membranous epidermoid cell
staining. Acinic cell carcinoma (4 cases) and Carcinoma
Ex-pleomorfic Adenoma (3 cases) positive cases displa-
yed focal weak to moderate membranous staining. The
Polymorphous low-grade (1 case) showed moderate pat-
chy of membranous staining, Adenocarcinoma (NOS) 5
cases and salivary duct carcinoma (2 cases) exhibited
Figure 1 Immunohistochemical staining for CD44 and CD24 A) CD44 positive (membrane staining) in case of mucoepidermoid
carcinoma (× 200) ; B) CD24 positive (membrane and cytoplasmic staining) in case of in case of mucoepidermoid carcinoma. (× 400)
(detail in right upper panel) C) CD44 positive (membrane staining was observed only on myoepithelial component) in case of adenoid cystic
carcinoma (× 200), D) Double immunohistochemical reaction of CD44 and CD24 in mucoepidermoid carcinoma. CD44 positive are indicated in
brown (DAB, membrane staining). CD24 positive cell are indicated in red (Fast red, cytoplasm), magnification x400.
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Table 1 Clinical features of the 69 SGMN patients
Male Female Total
% % %
Gender 28 40.6 41 59.4 69 100.00
Age ≤ 60 19 27.5 22 31.9 41 59.3
> 60 9 13.0 19 27.5 28 40.7
Smoking intake Yes 14 20.3 9 13.0 23 33.3
No 14 20.3 32 46.4 46 66.7
Alcohol intake Yes 9 13.0 5 7.2 14 20.3
No 19 27.5 36 52.2 55 70.3
Disease Classification MC 7 10.1 4 5.8 11 15.9
ACC 11 15.9 23 33.3 34 49.3
ACA 1 1.4 3 4.3 4 5.8
A.(nos) 4 5.8 1 1.4 5 7.2
BCA 2 2.9 3 4.3 5 7.2
PLGA 2 2.9 1 1.4 3 4.3
Cex-PA 0 0.0 4 5.8 4 5.8
SDC 1 1.4 2 2.9 3 4.3
PLSa PGb 10 14.5 17 24.6 26 37.7
SubM.Gc 8 11.6 5 7.2 13 18.8
SubL.Gd 0 0.0 2 2.9 2 2.9
MinorGe 10 14.5 17 24.6 27 39.1
Tumor Size T1 5 7.2 20 30.0 25 36.2
T2 12 17.4 5 7.2 17 24.6
T3 5 7.2 11 15.9 16 23.2
T4 6 8.7 5 7.2 11 15.9
Clinical Stage I 2 2.9 14 20.3 16 23.2
II 7 10.1 1 1.4 8 11.6
III 2 2.9 9 13.0 11 15.9
VI 17 24.6 17 24.6 34 49.3
Treatment Surgery 5 7.2 14 20.3 19 27.5
S. RT 11 15.9 19 27.5 30 43.5
S. CT. 3 4.3 1 1.4 4 5.8
S. RT and CT 9 13.0 7 10.1 16 23.2
Lymph node Negative 24 34.8 34 49.3 58 84.1
Positive 4 5.8 7 10.1 11 15.9
Metastasis No 15 21.7 28 40.6 43 62.3
Yes 13 18.8 13 18.8 26 37.7
Loco-regional No 17 24.6 28 40.6 45 65.2
recurrence Yes 11 15.9 13 18.8 24 34.8
Death No 15 21.7 33 47.8 48 69.6
Yes 13 18.8 8 11.6 21 30.4
RT: Radiotherapy; CT: Chemotherapy; a PLS: Primary Lesion Site; b PG: Parotid Gland; c SubM.G: Submandibular Gland; d SubL.G: Sublingual Gland; e MinorG: Minor
Salivary Glands. MC: mucoepidermoid carcinoma; ACC: adenoid cystic carcinoma; ACA: acinic cell adenocarcinoma; A (nos): adenocarcinoma; Cex-PA: carcinoma
ex-pleomorphic adenoma; SDC: salivary duct carcinoma; PLGA: polymorphous low-grade adenocarcinoma; BCA: basal cell adenocarcinoma (BCA); MMN: malignant
myoepithelial neoplasm.
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moderate focal areas of membranous staining, and Basal
Cell Adenocarcinoma (2 cases) exhibited weak diffuse
membranous staining throughout the tumoral islet.
However, the CD24 displayed focal weak to moderate
membranous/citoplasmatic staining in SGMN (mucoepi-
dermoid carcinoma 3 cases), adenoid cystic carcinoma (12
cases), carcinoma ex-pleomorphic adenoma (1 case), and
salivary duct carcinoma (2 cases).
The CD44 expression was associated with major sali-
vary gland topography (p = 0.046). CD24 expression was
associated with T stage (p = 0,27) and lymphnode metas-
tasis (p = 0,001). The 69 cases were grouped according
to CD44/CD24 profiles as follows: 36 cases (52.2%) were
CD44+/CD24-; 15 cases (21.7%); were CD44-/CD24-; 14
cases (20.3%) were CD44+/CD24+ (Figure 1D) and 4
cases (5.8%) were CD44-/CD24+. The profiles CD44/
CD24 correlated with primary lesion site (p = 0,005),
lymphnode metastasis (p = 0,011) and T stage (p = 0,023).
All of the immunohistochemical findings and relation-
ships to clinicopathologic features concerning the CD44/
CD24 profiles are summarized in Tables 2 and 3.
Univariate and multivariate analysis of SGMN survival
curves
The Kaplan-Meier analysis establish a significant relation-
ship between gender and OS (p = 0.011) and the present
data demonstrate that patients developing metastasis has
reduced its OS (p = 0.027). The univariate survival ana-
lysis also demonstrated a significant relationship between
clinical staging and DFS (p = 0.009). Kaplan–Meier tests
Table 2 Association of CD44 and CD24 with clinicopathological variables in 69 SGMN patients
CD44 CD24
+ - p + - p
Gender Male 19 (13.0%) 9 (13.0%) 0.330 6 (8.7%) 22 (31.9%) 0.330
Female 31 (44.9%) 10 (14.5%) 12 (17.4%) 29 (42.0%)
Age ≤ 60 30 (43.5%) 11 (15.9%) 0.543 10 (14.5%) 31 (44.9%) 0.453
> 60 20 (29.0%) 8 (11.6%) 8 (11.6%) 20 (29.0%)
Smoking intake Yes 15 (21.7%) 8 (11.6%) 0.250 5 (7.2%) 18 (26.1%) 0.392
No 35 (50.7%) 11 (15.9%) 13 (18.8%) 33 (47.8%)
Alcohol intake Yes 9 (13.0%) 5 (7.2%) 0.324 5 (7.2%) 9 (13.0%) 0.275
No 41 (59.4%) 14 (20.3%) 13 (18.8%) 42 (60.9%)
PLSa Majorb 34 (49.3%) 8 (11.6%) 0.046 11 (15.9%) 31 (44.9%) 0.605
Minorc 16 (23.2%) 11 (15.9%) 7 (10.1%) 20 (29.0%)
Tumor size T1/T2 28 (40.6%) 14 (20.3%) 0.142 7 (10.1%) 35 (50.7%) 0.027
T3/T4 22 (31.9%) 5 (7.2%) 11 (15.9%) 16 (23.2%)
Clinical Stage I / II 19 (27.5%) 6 (8.7%) 0.419 2 (2.9%) 23 (33.3%) 0.008
III / VI 31 (44.9%) 13 (18.8%) 16 (23.2%) 28 (40.6%)
Treatment Surgery 14 (20.3%) 5 (7.2%) 0.572 4 (5.8%) 15 (21.7%) 0.398
Sur. Adj. T.d 36 (52.2%) 14 (20.3%) 14 (20.3%) 36 (52.2%)
Metastasis No 32 (46.4%) 11 (15.9%) 0.421 10 (14.5%) 33 (47.8%) 0.339
Yes 18 (26.1%) 8 (11.6%) 8 (11.6%) 18 (26.1%)
loco-regional No 33 (47.8%) 12 (17.4%) 0.519 10 (14.5%) 35 (50.7%) 0.236
recurrence Yes 17 (24.6%) 7 (10.1%) 8 (11.6%) 16 (23.2%)
Lymph node Negative 43 (62.3%) 15 (21.7%) 0.352 10 (14.5%) 48 (69.6%) 0.001
Positive 7 (10.1%) 4 (5.8%) 8 (11.6%) 3 (4.3%)
Death No 36 (52.2%) 12 (17.4%) 0.332 14 (20.3%) 34 (49.3%) 0.285
Yes 14 (20.3%) 7 (10.1%) 4 (5.8%) 17 (24.6%)
CD24 Negative 36 (52.2%) 15 (21.7%) 0.398
Positive 14 (20.3%) 4 (5.8%)
CD44 Negative 4 (5.8%) 15 (21.7%) 0.398
Positive 14 (20.3%) 36 (52.2%)
a PLS: Primary Lesion Site; bMajor: Major Salivary Glands (Parotid Gland/Submandibular Gland/Sublingual Gland); cMinor; Minor Salivary Glands; dSur. Adj. T.:
Surgery with adjuvant therapy. Statistically significant difference (<0.05) by Fisher’s exact test (two variables) or χ2 (three or more variables) tests.
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also showed that CD44 expression had no statistical sig-
nificance when correlated to DFS or OS (p = 0.319 and
p = 0.447, respectively). CD24 expression, with respect
to OS and DFS, had no statistical significance (p = 0.519
and p = 0.081, respectively). The DFS and OS multivariate
analysis (Cox proportional hazard regression model) had
no statistical significance (p = 0.085 and p = 0.061, re-
spectively). Kaplan–Meier graphics for parameters that
had statistical significance are summarized in Figure 2.
Discussion
The literature shows that clinical staging is the main
prognostic factor for SGMN [3,30,31]. Our data are in
agreement with this assessment. The present study ob-
served patients in an advanced clinical stage (III/IV)
with relation to loco-regional recurrence. In our study,
clinical staging also correlated with DFS by Kaplan–
Meier tests. The clinical stage was proved to be an inde-
pendent prognostic factor in the studies of Bell et al.
[32] and Lima et al. [33]. Similar, the present study de-
monstrated that patients in an early clinical stage had a
better prognosis.
CD44 is main receptor for hyaluronate. CD44, 80 to
95KDa transmembrane protein has a pivotal role in cell-
extracellular matrix interaction [14]. Besides the extra-
cellular interaction with HA, fibronectin, collagen types
I and IV, serglycin and osteopontin [16] CD44 forms a
complexes with ERM (ezrin-radixin-moesin) to establish
a link with actin cytoskeleton [34].
The CD44 receptor is one of the most studied markers
for stem cells and is overexpressed in a large number of
solid neoplasms. Among the previous CD44 analyses in
epithelial tumors, some investigators found relation be-
tween this protein and stem cells behavior, suggesting
the CD44 as key marker of this cell population [22].
However, recently the role of CD44-expression in solid
neoplasms as a tumour marker for stem cells is discus-
sed and controversial.
Table 3 Association of CD44/CD24 immunophenotypes with clinicopathological variables in 69 SGMN patients
CD44/CD24 profilea
+/+ +/− −/+ −/− Total p
Gender Male 2 (2.9%) 17 (24.6%) 4 (5.8%) 5 (7.2%) 28 (40.6%) 0.091
Female 12 (17.4%) 19 (27.5%) 0 (0.0%) 10 (14.5%) 41 (59.4%)
Age ≤ 60 8 (11.6%) 22 (31.9%) 2 (2.9%) 9 (13.0%) 41 (59.4%) 0.967
> 60 6 (8.7%) 14 (20.3%) 2 (2.9%) 6 (8.7%) 28 (40.6%)
Smoking intake Yes 3 (4.3%) 12 (17.4%) 2 (2.9%) 6 (8.7%) 23 (33.3%) 0.554
No 11 (15.9%) 24 (34.8%) 2 (2.9%) 9 (13.0%) 46 (66.7%)
Alcohol intake Yes 2 (2.9%) 7 (10.1%) 3 (4.3%) 2 (2.9%) 14 (20.3%) 0.831
No 12 (17.4%) 29 (42.0%) 1 (1.4%) 14 (21.7%) 55 (79.7%)
PLSb Majorc 7 (10.1%) 27 (39.1%) 4 (5.8%) 4 (5.8%) 42 (60.9%) 0,005
Minord 7 (10.1%) 9 (13.0%) 0 (0.0%) 11 (15.9%) 27 (39.1%)
Tumor size T1/T2 4 (5.8%) 24 (34.8%) 3 (4.3%) 11 (15.9%) 42 (60.8%) 0.023
T3/T4 10 (14.5%) 12 (17.4%) 1 (1.4%) 4 (5.8%) 27 (39.1%)
Clinical Stage I / II 2 (2.9%) 17 (24.6%) 0 (0.0%) 6 (8.7%) 25 (36.2%) 0.098
III / VI 12 (17.4%) 19 (27.5%) 4 (5.8%) 9 (13.0%) 44 (63.8%)
Treatment Surgery 3 (4.3%) 11 (15.9%) 1 (1.4%) 4 (5.8%) 19 (27.5%) 0.807
Sur. Adj T.e 11 (15.9%) 25 (36.2%) 3 (4.3%) 11 (15.9%) 50 (72.5%)
Metastasis No 8 (11.6%) 24 (34.8%) 2 (2.9%) 9 (13.0%) 43 (62.3%) 0.790
Yes 6 (8.7%) 12 (17.4%) 2 (2.9%) 6 (8.7%) 26 (37.7%)
Loco-regional No 8 (11.6%) 25 (36.2%) 2 (2.9%) 10 (14.5%) 45 (65.2%) 0.711
Recurrence Yes 6 (8.7%) 11 (15.9%) 2 (2.9%) 5 (7.2%) 24 (34.8%)
Lymph node No 9 (13.0%) 34 (49.3%) 1 (1.4%) 14 (20.3%) 58 (84.0%) 0,011
Yes 5 (7.2%) 2 (2.9%) 3 (4.3%) 1 (1.4%) 11 (16.0%)
Death No 11 (15.9%) 25 (36.2%) 3 (4.3%) 9 (13.0%) 48 (69.6%) 0.556
Yes 3 (4.3%) 11 (15.9%) 1 (1.4%) 6 (8.7%) 21 (30.4%)
a +/+ cases CD44+/CD24+; +/− cases CD44+/CD24- and −/− cases CD44-/CD24-; −/− cases CD44-/CD24+. bPLS: Primary Lesion Site; cMajor: Major Salivary Glands
(Parotid Gland/Submandibular Gland/Sublingual Gland); dMinor; Minor Salivary Glands; eSur. Adj. T.: Surgery with adjuvant therapy. Statistically significant
difference (<0.05) by Fisher’s exact test (two variables) or χ2 (three or more variables) tests.
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The relation between CD44 and neoplasms presents
the breast cancer as the most well studied neoplasm; an
experimental assay demonstrates that tumors within
CD44-positive cell population possess cancer stem-cell
behavior (10). Similar to these results the cancer stem-
cell behavior of CD44-positive cells has also demonstra-
ted in head and neck squamous cell carcinomas [22].
Further findings demonstrate that CD44 expression
can be related to clinicopathological features and the ex-
pression of immunohistochemical markers of prognostic
significance. In an immunohistochemistry breast inva-
sive ductal carcinoma study Oliveira-Costa and collabo-
rators [35] demonstrated the relation between CD44
expression and HIF1-Alpha status and HER-2 expression
influencing the patient prognosis [35]. Choi and colla-
borators [36] observed an association between CD44
expression and tumour size studding colorectal adeno-
carcinoma. Notwithstanding, The patients outcome has
also been influenced in oral squamous cells carcinoma,
the CD44+ subpopulation was a independent factor of
a poor prognosis [37]. Nevertheless, the effect of CD44
expression on malignant neoplasms still demonstrates
conflicting results, some paper demonstrated that de-
creased CD44-expression could influence a worse prog-
nosis for the patient [20,21] in endometrioid carcinoma
the CD44-expression was observed and no association
was found between the protein expression and clinico-
pathological features suggesting that CD44-expression
predictive prognostic factor [38].
Examining salivary glands was demonstrated that
CD44v3 and v6 variants are widely expressed by myo-
epithelial and acinar cells, suggesting that these myo-
epithelial cells may play a critical role in normal salivary
gland renewal and may play a role in the control of
growth of salivary gland tumors considered to be derived
from modified myoepithelial cells [39]. Franchi and col-
leagues [40] reported an intense expression of CD44 and
CD44v6 in pleomorphic adenomas. This expression was
observed in tubular structures, solid areas and areas with
myxoid matrix or chondroid matrix production. They
also verified that malignant neoplastic cells in carcinoma
ex-pleomorphic adenoma cases were positive for CD44.
Our data provide an interesting find related between
CD44-expression and adenoid cystic carcinoma, was ob-
served an expression of CD44 in myoepithelial com-
ponent, however, the ductal component presents no
expression (Figure 1C). ACC has an indolent nature and
predilection to late distant metastasis [41]. ACC shares
histopathological features with PMLG. Thus transfor-
ming the diagnosis in a challenge to pathologists [42] to
decrease the diagnostic difficulty several markers were
suggested, an example is the proliferation marker MCM2
suggested by Ghazy and collaborators (2011) [43]. Suppor-
ted by our Immunohistochemical findings we also suggest
that CD44 could be used to differentiate borderline cases.
However, further studies with large number of cases are
recommended to support the idea. Our data has also pro-
vided evidence for a significant association between CD44
expression and SGMN in major salivary glands. This rela-
tionship was also suggested by the increased amount of
positive staining in major salivary glands tumors when
compared with neoplasms from minor salivary glands. A
hypothetical explanation for the differential expression of
CD44 could be the variation in histological features bet-
ween the salivary glands and/or embryological develop-
ment via the epithelium-mesenchyme relationship.
The CD24 receptor is a heavily-glycosylated protein
constructed of 27 amino acids attached to the cell mem-
brane by a GPI-anchor [44]. It was described as b-cell
marker, and its expression is associated with b-cell devel-
opment [24,45]. CD24 is related to P-selectin, an adhesion
receptor for platelets and activated endothelial cells [24].
The association between CD24 and P-selectin was
confirmed due to the interaction of mammary cancer cells
Figure 2 Univariated analysis. A) Kaplan-Meier plots of cumulative survival percentage in Disease free survival curve according to SGMN clinical
stage in the studied patients. B) Kaplan-Meier plots of cumulative survival percentage in Overall survival curve according to patients gender. C)
Kaplan-Meier plots of cumulative survival percentage in Overall Survival curve according to metastasis event in the studied patients. Statistically
significant difference (<0.05).
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and P-selectin in activated platelets [46]. This correlation
suggests that CD24 plays an important role in metastatic
events in human cancers [23].
CD24 is considered as a new marker for stem cells.
This cell surface glycoprotein is grouped together with
classical stem cells markers such as CD44, CD133 and
CD117. In animal models, the expression of CD24 is
observed in submandibular glands [47-49], Naduri and
colleagues [49] observed positive staining for CD24 in
the submandibular excretory duct. This expression sug-
gests a correlation between CD24 expression and the
development of branching epithelium. Our study has
shown positive CD24 expression in 9 SGMN cases. On
the other hand Ma and colleagues [50] reported that
metastatic adenoid cystic carcinoma cell lines lack CD24
expression. Our results, in conjunction with the results
of Ma and colleagues [50], indicate that CD24 expres-
sion is not well established in SGMN. Our analysis of
the CD24-positive cells in SGMN showed an association
between CD24 expression, T stage and clinical stage.
Cases that expressed CD24 were positively associated
TIII/TIV tumors and with cancer stages III / IV. These
results may suggest that CD24 correlates with advanced-
stage SGMN.
The present study found no correlations between
CD24 expression (total, cytoplasmic or membranous)
and overall survival. We have also found no correlations
between CD24 expression (total, cytoplasmic or mem-
branous) and disease free survival. Oliveira and colleagues
[37], studying oral squamous cell carcinoma, have also
found no relationship between total CD24 expression and
overall survival. However, the CD24-cytoplasmic expres-
sion showed a correlation with disease free survival and
overall survival. Kristiansen and colleagues [17] highligh-
ted that several studies analyzed only CD24-membranous
expression although CD24-cytoplasmatic expression is
usually presented as a prognostic factor for human
cancer.
Both CD44 and CD24 have been established as stem
cell surface markers and have been tested in several
groups of tissues and cancers [8-13]. The CD44/CD24
immunophenotypes behavior shows great diversity in
human cancers.
In lesions of invasive breast cancer, Mylona and col-
leagues [51] showed a correlation between the CD44+/
CD24- immunophenotype and negative lymph node me-
tastasis and lower staged tumors. However, this result dis-
agrees with the findings of Abraham and coworkers [52]
that suggested an association between the CD44+/CD24-
immunophenotype and distant metastasis but not with
the clinical outcome. In vitro findings suggest that breast
cancer cells with lymphatic metastatic ability and expres-
sing the CD44+/CD24- immunophenotype have clonoge-
nic potential and a higher ability to survive and grow in
unfavorable environments [53]. In human cases, however,
Giatromanolaki and colleagues [54] found that breast can-
cer patients that present with CD44-/CD24- cells had a
worsened overall survival.
Our data suggest that the relationship between CD44
and CD24 may have important role on clinicopatho-
logic features. The immunophenotype CD44+/CD24-
was the most prevalent, appearing in 52,2% of salivary
glands tumors. Except for the double negative pheno-
type (CD44-CD24-), all of the immunophenotypes had a
prevalent number of cases involving the major salivary
glands. This result may suggest a lower activity of stem
cells in minor salivary glands neoplasms. This finding
could have therapeutic implications. A lower stem cell ac-
tivity could result in an improved response to therapies
aimed at eradicating minor salivary gland tumors. These
diverse results reflect the controversial biological charac-
teristics described by Carrillo and coworkers [55] in minor
salivary gland neoplasms. Factors that may influence dis-
ease free survival rates are histological type, tumor grade
and clinical stage [1]. However, clinical stage is the prin-
cipal prognostic factor for predicting disease outcome
[1,3,30,31]. Our findings are in accordance with this litera-
ture-derived data.
The present study shows that SGMN with CD44+/
CD24+ profile may represents the tumors with most ag-
gressive behavior and worst prognosis. CD44+/CD24+
profiles was associated with tumor size and lymph node
metastasis. The majority of the CD44+/CD24+ cases
(66,6%) were classified as T3/T4 and the rate of positive
lymph node metastasis was higher than the expected
(35.7%). Thus, the double positive (CD44+/CD24+) pro-
file may be correlated with the more advanced tumors
and rapid disease development. This aggressive cell be-
havior was also demonstrated in CD44+/CD24+ pancre-
atic cancer cells. Injection of CD44+/CD24+ cells into
an animal model resulted in tumors a mere 3 weeks
after injection. The same results were not achieved with
CD44-/CD24- pancreatic cancer cells. These data dem-
onstrate the tumorigenic potential of pancreatic cancer
cells bearing the CD44+/CD24+ immunophenotype [12].
This phenomenon was also observed in the study con-
ducted by Huang and coworkers [56], where CD44+/
CD24+ pancreatic cancer cells showed an exacerbated
tumorigenic potential. Because stem cells from salivary
gland tissue and pancreatic tissue have similar capacities
for proliferation and differentiation, due to their similar
aggressive capacity, we can assume that the cancer stem
cell from both tissues also has similar abilities [57].
Conclusion
In summary, our investigation confirms that the clinical
stage, in accordance with the literature, is the main prog-
nostic factor for SGMN. Additionally, we have presented
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some evidence that the analysis of isolated CD44 and
CD24 immunoexpression or the CD44/CD24 immu-
nophenotypes could give a prognostic informations as-
sociated to clinicopathologic features Salivary Gland
Malignant Neoplasms.
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